FDA accepts Biohaven's Vyglxia resubmission for review in spinocerebellar ataxia

• Biohaven announced Oct. 22, 2026, that the FDA accepted its Vyglxia (troriluzole) application resubmission for review in spinocerebellar ataxia.
• The resubmission included new positive supportive analyses already submitted to the FDA.
• The agency deemed the resubmission a complete response to its Nov. 4, 2025, action letter.
• The FDA set a user fee goal date in the first quarter of 2027.
• The Peripheral and Central Nervous System Advisory Committee will review the application; its meeting date will be announced soon.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001935979-26-000083), on October 22, 2026, and is solely responsible for the information contained therein.